NORMAL SITUATION

MEEUS-DENEVE

Export PDF
Financial year 2023 · closed on 31/12/2023
Net result
7,2 k €
-73.9% YoY
Gross margin
6 k €
-90.1% YoY
Equity
109,9 k €
+0.0% YoY
Workforce
0,0 ETP
-100.0% YoY

Company — Normal situation.

What does MEEUS-DENEVE do?

MEEUS-DENEVE is a company registered in Belgium.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0824.444.867
Legal form
Private company with limited liability
Contributed capital
18 600,00 €
Latest accounts
31/12/2023
Average workforce
0,0 ETP
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 12 financial years

202320222021202020192018201720162015201420122011
Income statement
Gross margin6 k €60,9 k €56,5 k €87,7 k €52,7 k €101,5 k €87 k €106,3 k €114 k €124,2 k €111,6 k €197,6 k €
EBITDA5,4 k €47,1 k €36,7 k €68,8 k €34,4 k €82,9 k €70,9 k €87,1 k €95 k €104,7 k €84,4 k €144,5 k €
Operating result4,4 k €44,7 k €33,5 k €53,4 k €-21 k €28,2 k €16,8 k €30,1 k €31,2 k €40,4 k €23 k €44,5 k €
Net result7,2 k €27,7 k €17,7 k €38,5 k €-33 k €11,4 k €1,6 k €11,1 k €9 k €12,6 k €-2,9 k €-4,7 k €
Balance sheet
Equity109,9 k €109,9 k €69,7 k €52 k €13,5 k €46,5 k €35,1 k €33,5 k €22,4 k €13,5 k €-1,4 k €1,5 k €
Total assets118,4 k €128,8 k €265,1 k €240,1 k €257,2 k €308,2 k €351,3 k €424,3 k €479 k €552,9 k €651,5 k €710,7 k €
Cash2,7 k €20,6 k €79,6 k €31,7 k €36,3 k €33,1 k €29,5 k €39,5 k €51 k €61,9 k €48,6 k €51 k €
Debts8,4 k €18,9 k €192,7 k €185,4 k €241,1 k €251,1 k €309,8 k €388,6 k €443 k €526,4 k €640,7 k €699,4 k €
Other
Workforce0,0 ETP0,2 ETP––0,6 ETP0,6 ETP0,6 ETP0,6 ETP0,6 ETP0,6 ETP–0,9 ETP
Governance

Board of directors

Seen on filing of 31/12/2023 · 1 active · 4 ended

Active mandates

Pharma4Future

Director · since 01 octobre 2022 · 0776.403.737

Represented by Sven LENAERTS

Active

Ended mandates

Ariane Deneve

Director

Ended
Ariane Deneve

Manager

Ended
Roeland Meeus

Director

Ended
Roeland Meeus

Manager

Ended
Annual accounts

Full financial information

202320222021202020192018
Type of accountAbridged modelAbridged modelMicro modelMicro modelAbridged modelAbridged model
Start of the financial year01/01/202301/01/202201/01/202101/01/202001/01/201901/01/2018
Closing of the financial year31/12/202331/12/202231/12/202131/12/202031/12/201931/12/2018
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date09/07/202419/07/202314/07/202213/07/202116/07/202017/07/2019
General meeting20/06/202430/06/202316/06/202217/06/202118/06/202020/06/2019
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

13 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202320/06/202409/07/2024DutchPDF
Abridged model31/12/202230/06/202319/07/2023DutchPDF
Micro model31/12/202116/06/202214/07/2022DutchPDF
Micro model31/12/202017/06/202113/07/2021DutchPDF
Abridged model31/12/201918/06/202016/07/2020DutchPDF
Abridged model31/12/201820/06/201917/07/2019DutchPDF
Abridged model31/12/201721/06/201809/07/2018DutchPDF
Abridged model31/12/201615/06/201706/07/2017DutchPDF
Abridged model31/12/201516/06/201608/07/2016DutchPDF
Abridged model31/12/201418/06/201515/07/2015DutchPDF
Abridged model31/12/201319/06/201407/07/2014DutchPDF
Abridged model31/12/201220/06/201328/06/2013DutchPDF
Abridged model31/12/201121/06/201219/07/2012DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2023 · 1 active · 4 ended

Active mandates

Pharma4Future

Director · since 01 octobre 2022 · 0776.403.737

Represented by Sven LENAERTS

Active

Ended mandates

Ariane Deneve

Director

Ended
Ariane Deneve

Manager

Ended
Roeland Meeus

Director

Ended
Roeland Meeus

Manager

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Dissolution20/09/2024
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ... - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring19/06/2024
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Mandates24/10/2022
    ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2023
    Annual accounts 20237,2 k €↓
  2. 2022
    Annual accounts 202227,7 k €↑
  3. 2021
    Annual accounts 202117,7 k €↓
  4. 2020
    Annual accounts 202038,5 k €↑
  5. 2019
    Annual accounts 2019-33 k €↓
  6. 2018
    Annual accounts 201811,4 k €↑
  7. 2017
    Annual accounts 20171,6 k €↓
  8. 2016
    Annual accounts 201611,1 k €↑
  9. 2015
    Annual accounts 20159 k €↓
  10. 2014
    Annual accounts 201412,6 k €↑
  11. 2012
    Annual accounts 2012-2,9 k €↑
  12. 2011
    Annual accounts 2011-4,7 k €